News Releases

Date	Title and Summary	View
Jul 06, 2020	Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
Jul 01, 2020	Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine
Jun 30, 2020	Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Jun 26, 2020	Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Jun 15, 2020	New Phase 3 Data for TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Show Consistent, High Levels of Skin Clearance Through Four Years in Adult Patients with Moderate to Severe Plaque Psoriasis
Jun 13, 2020	Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
Jun 10, 2020	Johnson & Johnson to Participate in Bank of America Virtual Conference
Jun 10, 2020	Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
Jun 04, 2020	Johnson & Johnson to Host Annual Health for Humanity Investor Webcast Health for Humanity Webcast to Highlight Company's Commitment to Lead and Meet Urgent Health Challenges Worldwide Live Investor Webcast Scheduled for June 18, 2020 at 8:00 a.m. ET NEW BRUNSWICK, N.J. , June 4, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), the world's largest and most
Jun 04, 2020	European Commission Grants Marketing Authorisation for DARZALEX®▼(daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications